GlassScriptPhysician profile
Vinay Kamat
NPI 1760522916
$191,320.02
in general payments reported to CMS, 2019-2025
83 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,935 · 2020: $3,287 · 2021: $43K · 2022: $51K · 2023: $34K · 2024: $15K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Travel and Lodging: $11K · Food and Beverage: $6,559 · Education: $58.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,097.64 |
| Travel and Lodging | $10,602.64 |
| Food and Beverage | $6,558.82 |
| Education | $58.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174,001.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,166.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,157.77 | 2019-2024 | Farxiga, Breztri, Saphnelo |
| Lilly USA, LLC | $967.52 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $899.77 | 2019-2024 | Otezla, Repatha, Prolia |
| Horizon Therapeutics Plc | $888.28 | 2019-2023 | Krystexxa |
| Pfizer INC. | $853.19 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.92 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $629.86 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $595.92 | 2019-2025 | |
| Abbott Laboratories | $593.13 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $427.83 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.41 | 2019-2024 | Xifaxan, Ibschek |
| Merck Sharp & Dohme LLC | $380.12 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Currax Pharmaceuticals LLC | $373.41 | 2019-2023 | Nexletol, Contrave, Onzetra Xsail |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.